

# Colorectal Cancer™

U P D A T E

An Audio Review Journal for Nurses

**EDITOR**

Neil Love, MD

**INTERVIEWS**

Axel Grothey, MD

Nina Grenon, MS, APRN-BC, AOCN

Daniel G Haller, MD

Margot F Sweed, CRNP

*Additional comments by two people  
with colon cancer*



#### STATEMENT OF NEED/TARGET AUDIENCE

Medical oncology, particularly colorectal cancer, is one of the most rapidly advancing and developing fields of medicine. The constant emergence of new systemic agents, new indications for existing systemic agents, novel therapies, clinical trials and research findings demands that oncology nurses remain dedicated to continuing education in order to offer their patients the best care possible. This program provides registered nurses access to the most up-to-date research developments in colorectal cancer and the opinions of oncology nurses and clinical investigators with experience and expertise in the field. This information can be effectively translated into everyday patient management decisions.

#### PURPOSE STATEMENT

To present the most current research developments in colorectal cancer and to provide the perspectives of medical oncologists, oncology nurses and patients on the diagnosis and treatment of colorectal cancer.

#### EDUCATIONAL OBJECTIVES FOR THIS ISSUE OF *COLORECTAL CANCER UPDATE FOR NURSES*

- Explain the risks and benefits of chemotherapeutic agents and regimens in the adjuvant and metastatic settings.
- Explain the risks and benefits of biologic agents in the adjuvant and metastatic settings.
- Discuss nursing management of disease-related symptoms and treatment side effects.
- Discuss the clinical implications of emerging clinical trial data in colorectal cancer treatment and how to incorporate these data into management strategies in the adjuvant and metastatic settings.

#### ACCREDITATION STATEMENTS

This educational activity for 3 contact hours is provided by Research To Practice during the period of September 2007 through September 2008.

Research To Practice is an approved provider of continuing nursing education by the New Jersey State Nurses Association, Provider Number P215-01/07-10. NJSNA is accredited by the ANCC Commission on Accreditation. Provider Approval is valid through January 31, 2010.

#### HOW TO USE THIS CNE ACTIVITY

This is an audio CNE activity. This book contains a continuing nursing education Post-test and Evaluation Form, and the corresponding website [ColorectalCancerUpdate.com/Nurses](http://ColorectalCancerUpdate.com/Nurses) includes links to relevant full-text articles and abstracts. There are no fees for participating and receiving CNE credit for this activity. To receive credit during the period of September 2007 through September 2008, participants should read the learning objectives and faculty disclosures, listen to the CDs and complete the Post-test and Evaluation Form located in the back of this book and mail or fax to Research To Practice, or these can be completed on the [ColorectalCancerUpdate.com/Nurses](http://ColorectalCancerUpdate.com/Nurses) website.

*This program is supported by education grants from Genentech BioOncology and Sanofi-Aventis.*

If you would like to discontinue your complimentary subscription to *Colorectal Cancer Update for Nurses*, please email us at [Info@ResearchToPractice.com](mailto:Info@ResearchToPractice.com), call us at (800) 648-8654 or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.

## FACULTY AFFILIATIONS

**Axel Grothey, MD**

Senior Associate Consultant  
Department of Medical Oncology  
Mayo Clinic  
Rochester, Minnesota

**Daniel G Haller, MD**

Professor of Medicine  
Abramson Cancer Center  
at the University of Pennsylvania  
Philadelphia, Pennsylvania

**Nina Grenon, MS, APRN-BC, AOCN**

Adult/Geriatric Nurse Practitioner  
Center for Gastrointestinal Oncology  
Dana-Farber Cancer Institute  
Boston, Massachusetts

**Margot F Sweed, CRNP**

Nurse Practitioner  
GI Medical Oncology  
Fox Chase Cancer Center  
Philadelphia, Pennsylvania

## CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest, either current or within the past 12 months, for themselves (or their spouses/partners) that have been resolved through a peer review process: John Brebner, Richard Kaderman, PhD, Neil Love, MD, Paula Mateo, RN, BA, Anne O'Connor, RN, MSN, AOCN, Douglas Paley, Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Fredrica Preston, RNC, NP, AOCN, Ginelie Suarez, Erin Wall and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Aviva Asnis-Alibozek, PA-C, MPAS — salary: AstraZeneca Pharmaceuticals LP; shareholder of AstraZeneca Pharmaceuticals LP; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc and Genentech BioOncology. Research To Practice receives education grants from Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Genentech BioOncology/OSI Pharmaceuticals Inc, Genomic Health Inc, GPC Biotech, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

**Dr Grothey** — Consulting Fees: Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Roche Laboratories Inc, Sanofi-Aventis. **Ms Grenon** — Consulting Fees: Sanofi-Aventis; Speaker/Speakers Bureau: Amgen Inc, Roche Laboratories Inc, Sanofi-Aventis. **Dr Haller** — Consulting Fees: Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Roche Laboratories Inc, Sanofi-Aventis, Taiho Pharmaceutical Co; Other Financial Support: Genentech BioOncology, Roche Laboratories Inc, Sanofi-Aventis. **Ms Sweed** — Consulting Fees: Athena Forum; Speaker/Speakers Bureau: Meniscus Limited, Sanofi-Aventis.

*This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.*

## QUESTIONS (PLEASE CIRCLE ANSWER):

- In the MOSAIC and NSABP-C-07 adjuvant trials, the addition of \_\_\_\_\_ to 5-FU/leucovorin improved disease-free survival.**
  - Irinotecan
  - Oxaliplatin
  - Both a and b
  - None of the above
- In patients with colorectal cancer, surgical excision of oligometastatic disease in the liver is sometimes performed with curative intent.**
  - True
  - False
- Oxaliplatin is commonly associated with acute and cumulative \_\_\_\_\_.**
  - Hypertension
  - Epistaxis
  - Neuropathy
  - Proteinuria
- The \_\_\_\_\_ is the most common site of metastatic disease in patients with colorectal cancer.**
  - Lung
  - Liver
  - Bone
  - Brain
- A common first-line therapy in the treatment of metastatic colon cancer is FOLFOX combined with \_\_\_\_\_.**
  - Bevacizumab
  - Cetuximab
  - Irinotecan
- To adequately assess lymph node status of patients with colorectal cancer, it is recommended that at least \_\_\_\_\_ lymph nodes be examined.**
  - Five
  - Eight
  - 10
  - 12
- Data from the CONcePT study, in which patients with advanced colorectal cancer received oxaliplatin-based therapy and were randomly assigned to calcium and magnesium versus a placebo, demonstrated which of the following?**
  - Calcium and magnesium increased the response rate
  - Calcium and magnesium reduced the response rate
- Capecitabine is an oral form of which type of chemotherapy agent?**
  - Platinum
  - Irinotecan
  - Fluoropyrimidine
  - None of the above
- Data from the BRiTE observational study demonstrated a significant \_\_\_\_\_ in overall survival among patients with metastatic colorectal cancer who continued on bevacizumab after progression on a bevacizumab-containing regimen.**
  - Increase
  - Decrease
- The current standard adjuvant therapy for patients with Stage III colorectal cancer is \_\_\_\_\_.**
  - 5-FU/leucovorin/oxaliplatin
  - 5-FU/leucovorin/irinotecan
  - Cetuximab/irinotecan

## EVALUATION FORM

### Colorectal Cancer Update for Nurses — Issue 1, 2007

Research To Practice respects and appreciates your opinions. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this Evaluation Form. A statement of credit will be issued only upon receipt of a completed Evaluation Form and a completed Post-test with a score of 70 percent or better.

**Please answer the following questions by circling the appropriate rating:**

5 = Outstanding                      4 = Good                      3 = Satisfactory                      2 = Fair                      1 = Poor

#### EXTENT TO WHICH PROGRAM ACTIVITIES MET THE IDENTIFIED GOAL

- To present the most current research developments in colorectal cancer and to provide the perspectives of medical oncologists, oncology nurses and patients on the diagnosis and treatment of colorectal cancer..... 5 4 3 2 1

#### EXTENT TO WHICH PROGRAM ACTIVITIES MET THE IDENTIFIED OBJECTIVES

**Upon completion of this activity, participants should be better able to:**

- Explain the risks and benefits of chemotherapeutic agents and regimens in the adjuvant and metastatic settings..... 5 4 3 2 1
- Explain the risks and benefits of biologic agents in the adjuvant and metastatic settings..... 5 4 3 2 1
- Discuss nursing management of disease-related symptoms and treatment side effects..... 5 4 3 2 1
- Discuss the clinical implications of emerging clinical trial data in colorectal cancer treatment and how to incorporate these data into management strategies in the adjuvant and metastatic settings..... 5 4 3 2 1

#### EFFECTIVENESS OF THE INDIVIDUAL FACULTY MEMBERS

| Faculty                        | Knowledge of subject matter | Effectiveness as an educator |
|--------------------------------|-----------------------------|------------------------------|
| Axel Grothey, MD               | 5 4 3 2 1                   | 5 4 3 2 1                    |
| Nina Grenon, MS, APRN-BC, AOCN | 5 4 3 2 1                   | 5 4 3 2 1                    |
| Daniel G Haller, MD            | 5 4 3 2 1                   | 5 4 3 2 1                    |
| Margot F Sweed, CRNP           | 5 4 3 2 1                   | 5 4 3 2 1                    |

#### OVERALL EFFECTIVENESS OF THE ACTIVITY

- Will assist me in improving patient care..... 5 4 3 2 1
- Fulfilled my educational needs..... 5 4 3 2 1
- Avoided commercial bias or influence..... 5 4 3 2 1

#### IMPACT OF THE ACTIVITY

**The information presented (check all that apply):**

- Reinforced my current practice/treatment habits.                       Enhanced my current knowledge base.

## EVALUATION FORM

*Colorectal Cancer Update for Nurses — Issue 1, 2007*

### IMPACT OF THE ACTIVITY (CONTINUED)

Will the information presented cause you to make any changes in your practice?

- Yes       No

If yes, please describe any change(s) you plan to make in your practice as a result of this activity:

.....  
.....

If yes, how committed are you to making these changes?

(5 = very committed; 1 = not at all committed)..... 5 4 3 2 1

### FUTURE ACTIVITIES

Do you feel future activities on this subject matter are necessary and/or important to your practice?

- Yes       No

Please list any other topics that would be of interest to you for future educational activities:

.....  
.....

Additional comments about this activity:

.....  
.....

### FOLLOW-UP

As part of our ongoing, continuous quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey:

- Yes, I am willing to participate in a follow-up survey.       No, I am not willing to participate in a follow-up survey.

### REQUEST FOR CREDIT — please print clearly

Name:..... Degree:.....

Organization:..... Specialty:.....

Address: .....

City, State, Zip:.....

Telephone:..... Fax:..... Email:.....

Signature:..... Date:.....

Which of the following audio formats of this program did you use?

- Audio CDs       Downloaded MP3s from website

To obtain credit, complete the Post-test and Evaluation Form and mail to Research To Practice, 2 South Biscayne Blvd, Suite 3600, Miami, FL 33131, fax to (800) 447-4310 or complete both online. A statement of credit will be issued only upon receipt of a completed Post-test with a score of 70 percent or better and a completed Evaluation Form. Your statement of credit will be mailed to you within three weeks or may be printed online.

# Colorectal Cancer™

U P D A T E

|                                                       |                                                                                                                                                                                        |
|-------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Editor/CME Director</b>                            | Neil Love, MD                                                                                                                                                                          |
| <b>Managing Editor</b>                                | Kathryn Ault Ziel, PhD                                                                                                                                                                 |
| <b>Scientific Director</b>                            | Richard Kaderman, PhD                                                                                                                                                                  |
| <b>Senior Director, Medical Affairs</b>               | Aviva Asnis-Alibozek, PA-C, MPAS                                                                                                                                                       |
| <b>Writers</b>                                        | Lillian Sklaver Poltorack, PharmD<br>Douglas Paley                                                                                                                                     |
| <b>Continuing Education Administrator for Nursing</b> | Sally Bogert, RNC, WHCNP                                                                                                                                                               |
| <b>Content Validation</b>                             | Margaret Peng<br>John Brebner<br>Ginelle Suarez<br>Erin Wall                                                                                                                           |
| <b>Director, Creative and Copy Editing</b>            | Aura Herrmann                                                                                                                                                                          |
| <b>Creative Manager</b>                               | Fernando Rendina                                                                                                                                                                       |
| <b>Graphic Designers</b>                              | Jason Cunniss<br>Tamara Dabney<br>Shantia Daniel<br>Elisa Stambouli                                                                                                                    |
| <b>Senior Production Editor</b>                       | Alexis Oneca                                                                                                                                                                           |
| <b>Traffic Manager</b>                                | Tere Sosa                                                                                                                                                                              |
| <b>Copy Editors</b>                                   | Dave Amber<br>Margo Harris<br>Rosemary Hulce<br>Kirsten Miller<br>Pat Morrissey/Havlin<br>Carol Peschke<br>Susan Petrone                                                               |
| <b>Production Manager</b>                             | Rena Chiarelli                                                                                                                                                                         |
| <b>Audio Production</b>                               | Frank Cesarano                                                                                                                                                                         |
| <b>Web Master</b>                                     | John Ribeiro                                                                                                                                                                           |
| <b>Contact Information</b>                            | Neil Love, MD<br>Research To Practice<br>One Biscayne Tower<br>2 South Biscayne Boulevard, Suite 3600<br>Miami, FL 33131<br>Fax: (305) 377-9998<br>Email: NLove@ResearchToPractice.com |
| <b>For CNE Information</b>                            | Email: CNE@ResearchToPractice.com                                                                                                                                                      |

Copyright © 2007 Research To Practice. All rights reserved.

The compact discs, Internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their

own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

# Colorectal Cancer™

U P D A T E

Copyright © 2007 Research To Practice.  
This program is supported by education grants from  
Genentech BioOncology and Sanofi-Aventis.



Sponsored by Research To Practice.

Last review date: September 2007  
Release date: September 2007  
Expiration date: September 2008  
Contact hours: 3